BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 17, 2026
Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
Neurology/psychiatric RSS Feed RSS

Icons representing scientific research
The year in review

Science in 2025: the best of the rest

Jan. 2, 2026
By Anette Breindl and Mar de Miguel
No Comments
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Read More
Auvelity

Axsome’s Auvelity for Alzheimer’s agitation gets priority review

Dec. 31, 2025
By Karen Carey
No Comments
On the last day of the year, shares of Axsome Therapeutics Inc. rose 22% on news that the U.S. FDA accepted and granted priority review of the company’s supplemental NDA for AXS-05 to treat Alzheimer’s disease agitation, a $1 billion-plus opportunity, scheduling the PDUFA date for April 30.
Read More
Illustration of man holding magnifying glass to human body model showing muscle anatomy
Neurology/psychiatric

SPAST-AAV9 gene therapy prevents hereditary spastic paraplegia symptoms

Dec. 31, 2025
No Comments
In a recent publication in Molecular Therapy, researchers from Drexel University College of Medicine and UMass Chan Medical School presented a silence-and-replace gene therapy strategy aiming to address both the gain-of-toxicity and loss-of-function components of the disease hereditary spastic paraplegia (HSP).
Read More
Illustration of human brain and dna
Neurology/psychiatric

Gene therapy restores SynGAP1 function, rescues epilepsy and behaviors

Dec. 31, 2025
No Comments
SYNGAP1-related disorders (SRDs) are rare neurodevelopmental conditions characterized by a wide range of symptoms, including intellectual disability, epilepsy, motor deficits and increased risk-taking behavior.
Read More
Icons representing scientific research
The year in review

Science in 2025: the best of the rest

Dec. 31, 2025
By Anette Breindl and Mar de Miguel
No Comments
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.
Read More
Children’s Hospital of Philadelphia
The year in review

2025 marks a breakthrough year for in vivo gene therapies

Dec. 30, 2025
By Mar de Miguel
No Comments
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them.
Read More
Children’s Hospital of Philadelphia
The year in review

2025 marks a breakthrough year for in vivo gene therapies

Dec. 30, 2025
By Mar de Miguel
No Comments
Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them. However, many approaches still struggle to reach target cells or tissues – either they fail to arrive, or their efficacy is low. In vivo therapies face numerous challenges, but despite these hurdles, 2025 has marked a year of remarkable progress.
Read More
Neurology/psychiatric

New Nav1.8 blockers disclosed in Chengdu Easton Biopharmaceuticals patent

Dec. 30, 2025
Chengdu Easton Biopharmaceuticals Co. Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.
Read More
Neurology/psychiatric

Neurodawn Pharmaceutical divulges new PDE3A inhibitors

Dec. 30, 2025
Neurodawn Pharmaceutical Co. Ltd. has synthesized phosphodiesterase PDE3A inhibitors reported to be useful for the treatment of dementia and cerebrovascular disorders.
Read More
Demyelination of a neuron
Neurology/psychiatric

Apoptotic body-like liposomes restore immune tolerance in MS

Dec. 30, 2025
No Comments
Multiple sclerosis (MS) is a chronic immune-mediated disease characterized by the destruction of myelin sheaths, neuroaxonal damage, glial cell activation and formation of demyelinated plaques in the CNS. Since MS is considered a prototypic antigen-specific autoimmune disease, restoring immune tolerance to self-antigens is being explored as a therapeutic strategy.
Read More
Previous 1 2 … 36 37 38 39 40 41 42 43 44 … 3029 3030 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 16, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • CAR T and red blood cells

    Viva in vivo! At EHA, in vivo CAR T data continues to impress

    BioWorld
    Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing